In prior studies CDK4/6 [19] and PIM1 [15] have both been shown to be potential targets in renal cell carcinoma, making abemaciclib an attractive therapeutic agent. This evidence concerns the gene CDK4 and hereditary clear cell renal cell carcinoma.